ClinicalTrials.gg
CompletedNCT04382651MAS-COVIDUpdated Aug 10, 2022Results posted

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

A Phase 2 interventional study of MAS825 and Placebo in COVID-19 Pneumonia, Impaired Respiratory Function, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Enrollment
66th of 253
140 · median 42
Started
2020
with 41 others
Phase 2
28 of 349
3 open now
Registered
233rd of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 66th largest by enrollment of the 253 interventional ones that give a count, is one of 42 that started in 2020, is one of 28 in phase 2, and was the 233rd registered.

Respiratory Insufficiency

1,370 studies on the registry are indexed under Respiratory Insufficiency; 265 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.

Read the detailed description

This was a Phase 2, randomized, placebo -controlled, participant and investigator blinded, multi-center study to assess efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function.

The study consisted of five study periods:

Screening / Baseline / Treatment visit (Day -1 to 1): Lasted up to a maximum of 24 hours and comprised a screening / baseline assessment. This visit was used to confirm that the study inclusion and exclusion criteria were met and served as baseline assessment prior to randomization. Participants were randomized as soon as possible, but within a maximum of 24 hours after screening in a 1:1 ratio receiving a single intravenous infusion of MAS825 or placebo in addition to standard of care (SoC) on Day -1 to 1.

Treatment period (Day 2-15): Study assessments were conducted every 2 days for hospitalized participants. If participants were discharged from the hospital prior to Day 15, assessments on the day of discharge were performed according to the schedule listed under Day 15 and those participants returned to the site for the Day 15 assessment (all other visits between discharge and Day 15 were omitted).

Follow-up (Day 16-29): After completion of the treatment period, participants were observed until Day 29 or discharged from hospital, whichever was sooner. Study assessments were conducted every 2 days for domiciled participants. If participants were discharged from hospital prior to Day 29, a study visit conducted by telephone was performed on Day 29 (all other visits between discharge and Day 29 were omitted).

Safety follow-up visit assessment (Day 45): A follow-up visit for safety was conducted at Day 45 if the participant was hospitalized. If participants were discharged from the hospital prior to Day 45, a study visit was conducted by telephone on Day 45.

End of Study/Safety follow-up visit assessment (Day 127): A follow-up visit for safety was conducted at Day 127 if the participant was hospitalized. If participants were discharged from the hospital prior to Day 127, a study visit was conducted by telephone on Day 127.

03

Conditions studied

  • COVID-19 Pneumonia, Impaired Respiratory Function

Keywords

  • COVID-19
  • pneumonia
  • SARS-Cov2
  • APACHE II
  • MAS825
  • inflammasome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥18 years at screening
  2. Signed Form (ICF) by patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representative (if allowed according to local requirements)
  3. Clinically diagnosed with the SARS-CoV-2 virus by polymerase chain reaction (PCR) or by other approved diagnostic methodology within 7 days prior to randomization
  4. Hospitalized with COVID-19-induced pneumonia evidenced by chest x-ray, computed tomography scan (CT scan) or magnetic resonance scan (MR scan) (taken within 5 days prior to randomization)
  5. Impaired respiratory function, defined as peripheral oxygen saturation (SpO2) ≤93% on room air or partial pressure of oxygen (PaO2) / fraction of inspired oxygen (FiO2) \<300 millimeter of mercury (mmHg) at time of screening For cities located at altitudes greater than 2500 m above sea level, these will be substituted with SpO2 \<90% and PaO2/FiO2 \<250 mmHg
  6. Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II score of ≥10 at time of screening
  7. CRP ≥20 mg/L or ferritin level ≥600 μg/L at screening
  8. Body weight between 45 kg and 145 kg, inclusive, at screening
  9. Ability to comply with the study protocol, in the investigator's judgment

Exclusion criteria

Exclusion Criteria:

  1. History of to the treatment or their or to drugs of similar chemical classes
  2. Suspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral, or other infection with the exception of SARS-CoV-2
  3. In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment
  4. Intubated prior to randomization
  5. Patients who have explicitly expressed the wish not to receive intensive care support when this would be indicated based on their condition
  6. Previous treatment with anti-rejection and immunomodulatory drugs within the past 2 weeks, or within the past 30 days or 5 half-lives (whichever is the longer) for immunomodulatory therapeutic antibodies or prohibited drugs, with the exception of anti-viral therapies or

    • For COVID-19 infection, ongoing corticosteroid treatment is permitted at doses as per local SoC
    • For non-COVID-19 disorders, ongoing corticosteroid treatment is permitted at doses up to and including prednisolone 10 mg daily or equivalent.
  7. Serum (ALT) or aspartate transaminase (AST) >5 times detected within 24 hours at screening/baseline (according to local laboratory reference ranges) or other evidence of severe hepatic impairment.
  8. Absolute peripheral blood of ≤1000/mm\^3
  9. Estimated (eGFR) ≤30 mL/min/1.73m\^2 (based on CKD-EPI formula)
  10. Pregnant or breastfeeding, or positive urine or serum pregnancy test in a pre-dose examination
  11. Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  12. Women of , defined as all women physiologically capable of becoming pregnant, unless they agree to abstain from any sexual intercourse for a total of 29 days after randomization (the 14-day treatment period plus a 14-day follow-up period).
  13. Current participation in any other investigational trials, with the exception of (not yet) approved COVID-19 therapies that are considered (local) standard of care.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    MAS825 + SoC

    Single dose of MAS825 10 mg/kg by intravenous infusion in addition to SoC

    Drug: MAS825 · Drug: Standard of Care (SoC)

  • Placebo comparator
    Placebo + SoC

    Single dose of matching Placebo by intravenous infusion in addition to SoC

    Other: Placebo · Drug: Standard of Care (SoC)

Interventions

  • DrugMAS825

    MAS825 liquid solution for intravenous infusion

  • OtherPlacebo

    Placebo liquid solution for intravenous infusion

  • DrugStandard of Care (SoC)

    SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

06

What researchers measure

Primary outcomes

  1. APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)

    The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. In practice, it is rare for any participant to accumulate more than 55 points. APACHE II score was measured on Day 15 or on the day of discharge (whichever was earlier). Participants who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the participants at any time during the trial (worst case imputation for deaths). Missing data values of the parameters required for the derivation of the APACHE II score were replaced by the last available assessment.

    Time frame: up to Day 15

Secondary outcomes

  1. Serum C-reactive Protein (CRP) Levels

    C-reactive protein (CRP) is a blood test marker for inflammation in the body. It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.

    Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15

  2. Ferritin Levels

    Ferritin is a blood test marker for inflammation in the body. For a standard ferritin test, a normal reading is less than 300 micrograms per liter (μg/L). It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.

    Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15

  3. Number of Participants Not Requiring Mechanical Ventilation for Survival

    Number of participants not requiring mechanical ventilation for survival until Day 15 and Day 29: defined by WHO 9-point ordinal scale score of \< 6 points at all time points assessments. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.

    Time frame: Until Day 15 (Assessments on Days 2, 4, 6, 8, 10, 12, 14 and 15) and until Day 29 (Additional assessments on Days 17, 19, 21, 23, 25, 27 and 29)

  4. Number of Participants With at Least One-point Improvement From Baseline in Clinical Status

    Number of participants with at least one-point improvement from baseline in clinical status, which was measured with WHO 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.

    Time frame: Baseline, Day 15 and Day 29

  5. Clinical Status Over Time

    Clinical status was measured with World Health Organization (WHO) 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 127, the score for death was imputed for all following visits up to and including Day 127. For all the other participants, last observation carried forward was applied up to and including Day 127.

    Time frame: Baseline, days 2, 4, 6, 8, 10, 12, 14, 15, 17, 19, 21, 23, 25, 27, 29, 45 and 127

07

Results

Posted Apr 20, 2022

Participant flow

Participants took part in 21 investigative sites in 1 country, United States.

Participant flow — Overall Study
MilestoneMAS825 + SoCPlacebo + SoC
Started6971
Safety analysis set6870
Pharmacokinetics (pk) analysis set630
Completed3843
Not completed3128
Withdrew: Death2623
Withdrew: Lost to follow-up34
Withdrew: Withdrawal by subject20
Withdrew: Physician decision01

Outcome measures

PrimaryAPACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)

The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. In practice, it is rare for any participant to accumulate more than 55 points. APACHE II score was measured on Day 15 or on the day of discharge (whichever was earlier). Participants who died on Day 15 or earlier were assigned the highest observed APACHE II score of any of the participants at any time during the trial (worst case imputation for deaths). Missing data values of the parameters required for the derivation of the APACHE II score were replaced by the last available assessment.

Time frame:
up to Day 15
Reported as:
Least squares mean · Score on a scale
APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)
Score on a scaleMAS825 + SoCPlacebo + SoC
APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)14.5 ± 1.8713.5 ± 1.8
Statistical analysis
  • MAS825 + SoC vs Placebo + SoC · ANCOVA · p = 0.33 (1-Sided) · Mean difference (final values): 0.98 · 90% CI -2.7 to 4.7
SecondarySerum C-reactive Protein (CRP) Levels

C-reactive protein (CRP) is a blood test marker for inflammation in the body. It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.

Time frame:
Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15
Reported as:
Geometric least squares mean · Milligram / Liter
Serum C-reactive Protein (CRP) Levels
Milligram / LiterMAS825 + SoCPlacebo + SoC
Day 255.50 ± 1.1157.70 ± 1.10
Day 428.30 ± 1.1937.10 ± 1.19
Day 619.80 ± 1.2422.30 ± 1.24
Day 815.00 ± 1.3116.6 ± 1.30
Day 1010.10 ± 1.3819.80 ± 1.35
Day 1211.00 ± 1.4215.80 ± 1.39
Day 147.30 ± 1.4313.20 ± 1.39
Day 155.70 ± 1.4011.60 ± 1.36
SecondaryFerritin Levels

Ferritin is a blood test marker for inflammation in the body. For a standard ferritin test, a normal reading is less than 300 micrograms per liter (μg/L). It was analyzed on a log-scale fitting a repeated measures mixed model: treatment, visit, stratification factors, visit \* treatment and visit \* stratification factors as fixed effects and log-transformed baseline score and visit \* log-transformed baseline score as continuous covariate. Values reported were back-transformed to original scale.

Time frame:
Baseline, days 2, 4, 6, 8, 10, 12, 14 and 15
Reported as:
Geometric least squares mean · Microgram / Liter
Ferritin Levels
Microgram / LiterMAS825 + SoCPlacebo + SoC
Day 2773.20 ± 1.05800.20 ± 1.05
Day 4692.70 ± 1.05701.40 ± 1.05
Day 6687.50 ± 1.10622.10 ± 1.10
Day 8674.00 ± 1.12667.80 ± 1.11
Day 10670.00 ± 1.16776.00 ± 1.15
Day 12680.00 ± 1.18754.50 ± 1.17
Day 14541.70 ± 1.22595.70 ± 1.22
Day 15502.90 ± 1.21504.20 ± 1.21
SecondaryNumber of Participants Not Requiring Mechanical Ventilation for Survival

Number of participants not requiring mechanical ventilation for survival until Day 15 and Day 29: defined by WHO 9-point ordinal scale score of \< 6 points at all time points assessments. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.

Time frame:
Until Day 15 (Assessments on Days 2, 4, 6, 8, 10, 12, 14 and 15) and until Day 29 (Additional assessments on Days 17, 19, 21, 23, 25, 27 and 29)
Reported as:
Count of participants · Participants
Number of Participants Not Requiring Mechanical Ventilation for Survival
ParticipantsMAS825 + SoCPlacebo + SoC
Until Day 154147
Until Day 293945
SecondaryNumber of Participants With at Least One-point Improvement From Baseline in Clinical Status

Number of participants with at least one-point improvement from baseline in clinical status, which was measured with WHO 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 29, the score for death was imputed for all following visits up to and including Day 29. For all the other participants, last observation carried forward was applied up to and including Day 29.

Time frame:
Baseline, Day 15 and Day 29
Reported as:
Count of participants · Participants
Number of Participants With at Least One-point Improvement From Baseline in Clinical Status
ParticipantsMAS825 + SoCPlacebo + SoC
Day 153939
Day 294346
SecondaryClinical Status Over Time

Clinical status was measured with World Health Organization (WHO) 9-point ordinal scale. The scoring is - Uninfected patients have a score 0. - Ambulatory patients can have a score 1 (no limitation of activities) or 2 (limitation of activities). - Hospitalized patients with mild disease can have score 3 (no oxygen therapy) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (non-invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, renal replacement therapy, extracorporeal membrane oxygenation). - Patients who die have a score 8. Missing data values were handled as follows: For participants who died prior to Day 127, the score for death was imputed for all following visits up to and including Day 127. For all the other participants, last observation carried forward was applied up to and including Day 127.

Time frame:
Baseline, days 2, 4, 6, 8, 10, 12, 14, 15, 17, 19, 21, 23, 25, 27, 29, 45 and 127
Reported as:
Mean · Score on a scale
Clinical Status Over Time
Score on a scaleMAS825 + SoCPlacebo + SoC
Baseline4.8 ± 0.384.7 ± 0.49
Day 24.8 ± 0.714.7 ± 0.57
Day 44.8 ± 0.904.7 ± 1.13
Day 64.8 ± 1.274.7 ± 1.40
Day 84.9 ± 1.634.5 ± 1.64
Day 104.9 ± 1.764.6 ± 1.80
Day 125.0 ± 1.974.7 ± 2.04
Day 145.0 ± 2.044.8 ± 2.09
Day 154.5 ± 2.594.2 ± 2.58
Day 174.4 ± 2.644.2 ± 2.67
Day 194.4 ± 2.734.1 ± 2.70
Day 214.4 ± 2.784.1 ± 2.71
Day 234.4 ± 2.784.1 ± 2.73
Day 254.4 ± 2.794.2 ± 2.76
Day 274.4 ± 2.814.2 ± 2.76
Day 294.2 ± 2.993.8 ± 3.00
Day 454.0 ± 3.193.7 ± 3.24
Day 1273.8 ± 3.483.3 ± 3.41

Adverse events

Collected over Adverse events were reported from the date of administration of study treatment to day 127.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MAS825 + SoC26/68 (38.2%)31/68 (45.6%)20/68 (29.4%)
Placebo + SoC23/70 (32.9%)28/70 (40%)19/70 (27.1%)
Total49/138 (35.5%)59/138 (42.8%)39/138 (28.3%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventMAS825 + SoCPlacebo + SoCTotal
Acute respiratory failureRespiratory, thoracic and mediastinal disorders11/688/7019/138
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders6/680/706/138
HypoxiaRespiratory, thoracic and mediastinal disorders5/681/706/138
Respiratory failureRespiratory, thoracic and mediastinal disorders5/685/7010/138
COVID-19 pneumoniaInfections and infestations2/684/706/138
Acute kidney injuryRenal and urinary disorders3/684/707/138
Septic shockInfections and infestations3/680/703/138
Cardiac arrestCardiac disorders2/683/705/138
PancytopeniaBlood and lymphatic system disorders2/680/702/138
Multiple organ dysfunction syndromeGeneral disorders2/681/703/138
Most frequent other events
Most frequent other events
EventMAS825 + SoCPlacebo + SoCTotal
Acute kidney injuryRenal and urinary disorders9/685/7014/138
Pneumonia bacterialInfections and infestations6/682/708/138
AnxietyPsychiatric disorders3/686/709/138
HypotensionVascular disorders5/683/708/138
Urinary tract infectionInfections and infestations2/685/707/138
Transaminases increasedInvestigations0/685/705/138
Atrial fibrillationCardiac disorders4/684/708/138

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MAS825 + SoCPlacebo + SoCTotal
Mean65.3 ± 12.4663.7 ± 12.9164.5 ± 12.67
Sex: Female, Male
Sex: Female, Male(Participants)MAS825 + SoCPlacebo + SoCTotal
Female302353
Male394887
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MAS825 + SoCPlacebo + SoCTotal
American Indian or Alaska Native022
Asian314
Native Hawaiian or Other Pacific Islander314
Black or African American6814
White5152103
More than one race000
Unknown or Not Reported6713
08

Study locations

21 sites
  • Novartis Investigative Site
    Chula Vista, California 91911, United States
  • Novartis Investigative Site
    Glendale, California 91206, United States
  • Novartis Investigative Site
    Irvine, California 92697, United States
  • Novartis Investigative Site
    La Mesa, California 91942, United States
  • Novartis Investigative Site
    Santa Monica, California 90404, United States
  • Novartis Investigative Site
    Torrance, California 90503, United States
  • Novartis Investigative Site
    Denver, Colorado 80220, United States
  • Novartis Investigative Site
    Washington, District of Columbia 20037, United States
  • Novartis Investigative Site
    Idaho Falls, Idaho 83404, United States
  • Novartis Investigative Site
    Alexandria, Louisiana 71301, United States
  • Novartis Investigative Site
    Baton Rouge, Louisiana 70809, United States
  • Novartis Investigative Site
    Lafayette, Louisiana 70596, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02115, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02118, United States
  • Novartis Investigative Site
    Brooklyn, New York 11219, United States
  • Novartis Investigative Site
    Asheville, North Carolina 28805, United States
  • Novartis Investigative Site
    Columbus, Ohio 43214, United States
  • Novartis Investigative Site
    Bend, Oregon 97701, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19140, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Mesquite, Texas 75149, United States
09

References and documents

Publications

  • Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. PubMed 34473343 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jan 2021, 6 months.

Results were first posted in Apr 2022, 1 year 3 months after primary completion. A results delay was requested in Jul 2021.

Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2020
First posted
May 11, 2020
StartActual
Jun 11, 2020
Primary completionActual
Jan 6, 2021
CompletionActual
Apr 21, 2021
Results delay requested
Jul 7, 2021
Results first posted
Apr 20, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04382651
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Jun 11, 2020
Primary completion
Jan 6, 2021
Completion
Apr 21, 2021
Results posted
Apr 20, 2022
Last update
Aug 10, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arumakimig

Start the discussion